Immatics

Immatics EBITDA per Employee

The EBITDA per Employee of Immatics (IMTX) as of Nov 19, 2026 is -598,736.84 EUR. In the previous year, EBITDA per Employee was -98,049.34 EUR — a change of 510.65% (lower).

EBITDA per Employee

-598,736.84EUR

YoY

510.65%

Last updated:

EBITDA per Employee of Immatics is 2025 -598,736.84 EUR. EBITDA per Employee of Immatics was 2024 -98,049.34 EUR. It decreases by 510.65% lower compared to the previous year.

The Immatics EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-105,950.66 EUR
Jan 1, 2019
-102,342.11 EUR
Jan 1, 2020
-222,088.82 EUR
Jan 1, 2021
-274,957.24 EUR
Jan 1, 2022
109,388.16 EUR
Jan 1, 2023
-323,075.66 EUR
Jan 1, 2024
-98,049.34 EUR
Jan 1, 2025
-598,736.84 EUR
The Immatics EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-598,736.84EUR+510.65%
-98,049.34EUR-69.65%
-323,075.66EUR-395.35%
109,388.16EUR-139.78%
-274,957.24EUR+23.81%
-222,088.82EUR+117.01%
-102,342.11EUR-3.41%
-105,950.66EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immatics Stock analysis

What does Immatics do? Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors through Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). The company's pipeline includes eight therapeutic programs, with four in clinical trials: IMA201 (MAGEA4/8), IMA202 (MAGEA1), ACTolog IMA 101 (Multi-target pilot trial), and IMA203 (PRAME). Four programs are in preclinical development, such as IMA204 (COL6A3) and IMA401 (Cancer testis antigen). Immatics generates revenue through licensing agreements and potential future sales of its therapies, targeting pharmaceutical companies and research institutions seeking advanced cancer treatments. The company's clinical-stage therapies are designed to enable robust T-cell responses against cancer targets, with programs like IMA201 and IMA202 focused on solid tumors. IMA203 addresses both hematological and solid cancers, while preclinical programs like IMA401 and IMA402 target cancer testis antigens. Immatics partners with biopharmaceutical firms to advance its pipeline, leveraging its TCR technology platform to develop therapies for unmet medical needs in oncology. Immatics' revenue model relies on strategic partnerships and licensing deals with pharmaceutical companies, which fund clinical development and gain access to its proprietary TCR platform. The firm's focus on solid tumors and hematological cancers attracts interest from major biopharmaceutical players looking to expand their oncology portfolios. Through its eight therapeutic programs, Immatics aims to deliver innovative treatments that address high unmet medical needs in cancer therapy. Immatics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immatics stock

EBITDA per Employee of Immatics is -598,736.84 EUR in 2025.

EBITDA per Employee of Immatics changed from -98,049.34 EUR to -598,736.84 EUR, representing a 510.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Immatics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Immatics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Immatics

All Key Metrics — Immatics